Results:
Tag: COVID -19

Biden Administration announces U.S. government procurement of Merck’s investigational antiviral medicine for COVID-19 treatment
June 9, 2021

Memorandum of Understanding for Acquisition Support Signed Between the Department of Defense and the Department of Health and Human Services
May 26, 2021

Interview with Dr. Kevin Wingerd Chief Technology Officer at the Joint Project Manager for Chemical, Biological, Radiological, and Nuclear Medical (JPM CBRN Medical)
May 25, 2021

The COVID-19 Pandemic: Acquisition of Diagnostic Equipment and Testing Assays for COVID-19 Lays the Groundwork for Vaccine and Treatment Success
May 25, 2021

DOD & HHS Announce DPA Title III Agreement With Retractable Technologies, Inc. to Expand Domestic Production Capacity for Low Dead-Space Safety Syringes and Needles
May 24, 2021

Sanofi-GSK report positive interim results for their COVID-19 shot
May 17, 2021

Using Ultrasound Stimulation to Reduce Inflammation in COVID-19 In-Patients
May 12, 2021

INOVIO Announces Positive Data from Phase 2 Segment of Clinical Trial Evaluating INO-4800, its COVID-19 DNA Vaccine
May 10, 2021

Immunome SARS-CoV-2 Antibody Cocktail Neutralizes UK, South Africa, Brazil and California Variants in Preclinical Testing; Progressing Towards IND Filing
April 26, 2021

SAB Biotherapeutics Doses First Patient with SAB-185 for the Treatment of COVID-19 in NIH’s ACTIV-2 Phase 2/3 Clinical Trial
April 21, 2021


JPEO-CBRND Press Kit

Download our press kit, which includes helpful documents to better understand our work, such as – Command Brief, Chemical Biological Defense Program's Enterprise strategy, the JPEO-CBRND's Capabilities Catalog, Leadership Biographies, COVID-19 fact sheets, and contracting overview documents.  

 

 


JPEO-CBRND Public Affairs Office

The JPEO-CBRND Communications Affairs Network coordinates and responds to all Public Affairs needs on behalf of the JPEO-CBRND. To request a speaker, subject matter expert, or for other interview or request for comment please email our Public Affairs Office email below.